Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tarlatamab + AMG 404
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**tarlatamab + AMG 404** is an investigational combination therapy studied primarily for the treatment of small cell lung cancer (SCLC). Tarlatamab (AMG 757) is a half-life extended bispecific T-cell engager (BiTE) molecule that binds both delta-like protein 3 (DLL3), a target highly expressed in SCLC tumor cells, and CD3 on T cells, thereby redirecting T-cell cytotoxicity toward DLL3-positive tumor cells. AMG 404 is a fully human monoclonal antibody that targets the programmed cell death 1 (PD-1) receptor, functioning as a checkpoint inhibitor to block the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby augmenting T-cell responses against tumors. The combination is designed to enhance antitumor activity by addressing both targeted tumor cell killing and overcoming immunosuppressive mechanisms in the tumor microenvironment. The combination is being developed and tested by Amgen in phase 1b clinical trials in adults with SCLC who have progressed after platinum-based chemotherapy[1][2][3][4].
- Other names
- tarlatamab + AMG 404
02
Targets
CD3 (T-cell surface glycoprotein CD3)DLL3 (Delta-like ligand 3)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tarlatamab + AMG 404.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tarlatamab + AMG 404.